BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Soluble Therapeutics to Launch HSC™ Technology at BioProcess International Conference


10/9/2012 10:04:50 AM

BIRMINGHAM, Ala., Oct. 9, 2012 /PRNewswire/ -- Birmingham-based Soluble Therapeutics, Inc, today announced the official launch of its high-throughput second viral coefficient determination system, HSC Technology, at the IBC BioProcess International Conference in Providence, RIOctober 8-12.

HSCTM Technology was developed by Dr. Bill Wilson, former Chairman, Chemistry Department at Mississippi State University, and former NASA astronaut, Dr. Larry DeLucas, Director of the Center for Biophysical Sciences & Engineering at the University of Alabama Birmingham. Doctors Wilson and DeLucas have collaborated for the last two decades on the development of the HSCTechnology. http://www.youtube.com/watch?v=J1PwehpiV-I.

"Conventional methods used to identify formulations promoting solubility and stability of proteins often cost hundreds of thousands of dollars," said Dr. Joseph N. Garner, CEO, Soluble Therapeutics. Inc. "HSC Technology accelerates the formulation process, achieving in a month what can take a team of scientists a year or longer to achieve. Since significantly less protein is required for optimization, HSC is an incredibly efficient way to get past the formulation bottleneck."

Companies developing biotherapeutics face the challenge of keeping therapeutic proteins soluble and stable at high concentrations. The HSCsystem helps researchers and manufacturers overcome this challenge by reducing time and costs, while accelerating the progression of candidates through the development pipeline.

HSC Technology is a self-contained, automated, chromatographic system that conducts high-throughput, microcapillary, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations. The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination(s) of additives and excipients, resulting in increased solubility and physical stability of proteins. The system works in concert with a predictive algorithm of formulation parameters that can be exclusively accessed through Soluble Therapeutics.

The HSCInstrument, and underlying technology, has been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic. For academic collaborators, this has meant further progression of structural biology studies necessary to advance research in areas of unmet medical need.

Soluble Therapeutics, Inc. has received over $1 million in grant funding from the National Institutes of Health, which is being utilized to advance applications of the HSC Technology.

About Soluble Therapeutics, Inc.
Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC Technology. The company's services enhance the drug development process, by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics' management team consists of science industry professionals bringing over 60 years combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first company to introduce protein formulation solutions that deliver the price and performance advantages of the HSC Technology.

For additional information visit www.soluble-therapeutics.com

SOURCE Soluble Therapeutics, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES